What are PresVu eye drops?
PresVu is a specially formulated eye drop developed by Entod Pharmaceuticals to target presbyopia – a condition that affects individuals over the age of 40. Presbyopia occurs when the eye’s natural lens loses its flexibility, making it difficult to focus on close objects. This is a natural part of ageing and mostly leads to the use of reading glasses. PresVu aims to address this issue by improving the eye’s focusing ability, thereby reducing the need for reading glasses.
Top Ayurvedic herbs for making your eyes sharp and healthy
How does PresVu work?
PresVu works by temporarily improving the flexibility of the eye’s lens, which deteriorates with age. When applied, the eye drop stimulates the muscles around the lens, helping it to change shape more easily and focus on nearby objects. This improvement in focusing ability allows people with presbyopia to see clearly at close range without the constant need for reading glasses. Entod Pharmaceuticals describes PresVu as a “solution that stands to improve the lives of millions by offering them greater visual independence,” as stated by CEO Nikkhil K Masurkar.
Who can benefit from PresVu?
PresVu is designed for individuals who have been diagnosed with presbyopia and are looking for alternatives to reading glasses. According to industry estimates, between 1.09 to 1.8 billion people worldwide are affected by presbyopia, making this eye drop a potential solution for a large segment of the population. PresVu helps in reducing dependency on reading glasses which can provide a significant quality-of-life improvement for those who find glasses cumbersome or inconvenient.
Impact of eyecare in India
As the first eye drop in the country specifically developed for presbyopia, it opens new possibilities for treating this common condition. “This DCGI approval is a major step forward in our mission to transform eye care in India,” noted Masurkar. The introduction of PresVu is expected to cater not only to the domestic market but also to emerging markets in Africa and Southeast Asia, where access to innovative eye care solutions is limited.
(With inputs from PTI)